Abstract | OBJECTIVE: METHODS: In this observational study, between August 2016 and July 2019, 15 patients with seropositive PR with inadequate response to HCQ (≥ 2attacks per month even after 6 months of therapy) were included. All patients were treated with oral low dose methotrexate in addition to HCQ. The responses to therapy were monitored 3 and 6 months after adding methotrexate. RESULTS: In our study, of the 15 patients with PR, two-third were female, with a mean age of 45.73±9.18 years. All were seropositive ( Rheumatoid factor positive in eight patients; anti- cyclic citrullinated peptide [CCP] positive in 11 patients; both Rheumatoid factor and anti-CCP positive in four patients). The average number of attacks at baseline was 5.6±2.8, and the median duration of attacks was 2 years. All patients had significant response to add-on methotrexate therapy at follow-up after 3 and 6 months; none developed Rheumatoid arthritis (RA) after 2 years of follow-up. CONCLUSION: Low dose methotrexate is an effective add-on therapy in patients with PR having inadequate response to HCQ.
|
Authors | Prasanta Padhan, Bhaskar Thakur |
Journal | European journal of rheumatology
(Eur J Rheumatol)
Vol. 8
Issue 3
Pg. 130-132
(Jul 2021)
ISSN: 2147-9720 [Print] Turkey |
PMID | 34101572
(Publication Type: Journal Article)
|